Impaired interleukin-2 production in T-cells from a patient with Wiskott-Aldrich syndrome : basis of clinical effect of interleukin-2 replacement therapy

Interleukin-2 production may be one of the underlying causes of Wiskott-Aldrich syndrome immunodeficiency and recombinant interleukin-2 administration (or an infusion of T-cells expanded by CD3 stimulation and rIL-2) is able, to some extent, to restore defective T-cell function.

Saved in:
Bibliographic Details
Published in:European journal of pediatrics 2000-08, Vol.159 (8), p.633-634
Main Authors: AZUMA, H, OSHIMA, M, IKEDA, H, ITO, K, OKUNO, A, KAWABATA, I, BANBA, K, MURAHASHI, H, SEKINE, T, KATO, Y, IKEBUCHI, K
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal - immunology
Antibodies, Monoclonal - therapeutic use
Biological and medical sciences
CD3 Complex - immunology
Hematologic and hematopoietic diseases
Humans
Interleukin-2 - immunology
Interleukin-2 - therapeutic use
Medical sciences
Platelet diseases and coagulopathies
Recombinant Proteins - therapeutic use
Wiskott-Aldrich Syndrome - blood
Wiskott-Aldrich Syndrome - immunology
Wiskott-Aldrich Syndrome - therapy
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Interleukin-2 production may be one of the underlying causes of Wiskott-Aldrich syndrome immunodeficiency and recombinant interleukin-2 administration (or an infusion of T-cells expanded by CD3 stimulation and rIL-2) is able, to some extent, to restore defective T-cell function.
ISSN:0340-6199
1432-1076
DOI:10.1007/PL00008395